Education and Exercise to Prevent Lymphedema
Name of the Trial
Randomized Study of Education with or without Exercise and Counseling in Preventing Lymphedema in Women with Stage I-III Breast Cancer Who Are Undergoing Axillary Lymph Node Dissection (CALGB-70305). See the protocol summary at http://cancer.gov/clinicaltrials/CALGB-70305.
Principal Investigator
Dr. Electra Paskett, Cancer and Leukemia Group B
Why This Trial Is Important
Surgery for breast cancer may include the removal and examination of lymph nodes in the underarm area near the affected breast (called axillary node dissection). This procedure allows doctors to determine whether cancer has spread to the lymphatic system. A common side effect of axillary node dissection is lymphedema, a swelling of the arm and/or hand on the same side as surgery caused by the buildup of lymphatic fluid. Lymphedema is often debilitating.
There is no known cure for lymphedema, but some measures can make it easier to live with or possibly prevent it. Women who undergo axillary node dissection should receive education about how to recognize and possibly prevent lymphedema.
This study compares a lymphedema-prevention education program to the same education program supplemented with an exercise regimen and counseling in women who have been newly diagnosed with breast cancer and who will undergo axillary node dissection. Researchers want to see if education, exercise, and counseling will help prevent lymphedema or limit its severity if it develops.
"As many as one-third of women who undergo full axillary node dissection will experience lymphedema," said Dr. Paskett. "These women may suffer serious physical, social, and psychological effects because of this condition. We hope these interventions will help breast cancer survivors enjoy a better quality of life."
Who Can Join This Trial
Researchers will enroll 560 women aged 18 and over newly diagnosed with stage I-III breast cancer who will undergo an axillary node dissection with 10 or more lymph nodes removed. See the list of eligibility criteria at http://cancer.gov/clinicaltrials/CALGB-70305.
Study Sites and Contact Information
Study sites in the United States are recruiting patients for this study. See the list of study contacts at http://cancer.gov/clinicaltrials/CALGB-70305#ContactInfo_CDR0000494652 or call the NCI's Cancer Information Service at 1-800-4-CANCER (1-800-422-6237) for more information. The toll-free call is confidential.
An archive of "Featured Clinical Trial" columns is available at http://cancer.gov/clinicaltrials/ft-all-featured-trials. |